LEGENDS
FIGURE 1 Effect of daratumumab on the patient’s total white cell count (x 109/L) and absolute (peripheral) blast count (x 109/L) over time in days: 2 doses of daratumumab administered on day 1 and day 8, with an initial reduction in WCC and ABC between day 3 and day 10. WCC and ABC rose from day 11 until FLA-Ida commenced at day 14. See Supplemental table 1 for further laboratory values. WCC, white cell count; ABC, absolute blast count; Dara, daratumumab; FLA-Ida, fludarabine, high-dose cytarabine, idarubicin